



## CHANDAN HEALTHCARE LIMITED

Reg. Off. Add: Biotech Park, Sector-G, Jankipuram, Kursi Road, Lucknow-226021

CIN: L85110UP2003PLC193493

TELNO.: -8069366666 Email: [secretarial@chandan.co.in](mailto:secretarial@chandan.co.in)

[www.chandandiagnostic.com](http://www.chandandiagnostic.com)

---

**Date: June 01, 2026**

To,  
The Manager  
Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza, Bandra Kurla Complex  
Bandra (East), Mumbai – 400051

**Symbol: CHANDAN**  
**ISIN: INE0B2N01016**

**Sub: Submission of Press Release on Audited Financial Results for the Quarter and Financial Year ended March 31, 2026**

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith a copy of the Press Release issued by the Company titled “Chandan Healthcare Reports FY26 Total Income of Rs.280.67 Cr with EBITDA of Rs.56.84 Cr and PAT of Rs.27.06 Cr” in connection with the Audited Financial Results of the Company for the quarter and financial year ended March 31, 2026.

The aforesaid Press Release is being disseminated to the media and is also being made available on the website of the Company.

Kindly take the same on record.

Thanking You,

**For Chandan Healthcare Limited**

**Rajeev Kumar Nain**  
**Company Secretary & Compliance Officer**

**Encl: as above**



## Chandan Healthcare Reports FY26 Total Income of ₹280.67 Cr with EBITDA of ₹56.84 Cr and PAT of ₹27.06 Cr

Lucknow, India – 28<sup>th</sup> May, 2026 Chandan Healthcare Limited (NSE - CHANDAN), – Chandan Healthcare Limited, one of the leading players in Diagnostic sector having Pan India presence, has announced its audited Financial Results for Q4 FY26 & FY26.

### Consolidated Key Financial Highlights:

Particulars (₹ Cr)	FY26	FY25	YoY
Total Income	280.67	233.06	↑ 20.43%
EBITDA	56.84	43.39	↑ 31.02%
EBITDA Margin (%)	20.25%	18.62%	↑ 164 Bps
PAT	27.06	22.17	↑ 22.04%
PAT Margin (%)	9.64%	9.51%	↑ 13 Bps

Particulars (₹ Cr)	Q4 FY26	Q4 FY25	YoY
Total Income	77.41	65.07	↑ 18.96%
EBITDA	14.25	12.65	↑ 12.65%
PAT	6.92	6.02	↑ 14.88%

For more details, visit the company's website: <https://chandandiagnostic.com/>

Note: During the period, pursuant to the **implementation of the New Labour Codes** and the resultant change in the definition of wages, **the Company recognised additional defined benefit obligations** based on actuarial valuation in accordance with Accounting Standard (AS) 15 – Employee Benefits. The impact pertaining to employee service in prior periods has been recognised as past service cost and disclosed as an Exceptional Item. **Accordingly, an amount of ₹0.69 Cr for Q4 FY26 and ₹2.92 Cr for FY26 has been recognised as a one time and non-recurring adjustment.**

**Commenting on the financial performance, Mr. Amar Singh, Promoter and Chairman & Managing Director of Chandan Healthcare Limited, said,** “We are pleased to conclude FY26 on a strong note with Total Income of ₹280.67 Cr, EBITDA of ₹56.84 Cr and PAT of ₹27.06 Cr. FY26 has been a year of aggressive expansion, strategic investments and network scale-up for Chandan Healthcare as we continued to strengthen our operational presence across multiple regions while building long-term growth capabilities for the business.

During the quarter, we expanded our network through new diagnostic centre launches in Mumbai, Kolkata and Raipur while also accelerating the rollout of our exclusive partnership with Jeena Sikho across 13 states including Chandigarh, Bihar, West Bengal, Chhattisgarh, Madhya Pradesh, Maharashtra, Gujarat, Assam, Delhi, Punjab, Haryana, Uttar Pradesh and Uttarakhand. We also strengthened our institutional healthcare presence through multiple long-term government healthcare projects across Punjab, Haryana and Assam, supporting long-term revenue visibility and expanding our advanced radiology capabilities across key healthcare markets.

During the year, we also acquired a comprehensive diagnostic centre in Patna, Bihar offering both pathology and radiology services, further strengthening our regional presence. The Company also expanded into the franchisee business model and **successfully launched more than 130 franchise centres during FY26**. Building on this momentum, we are **targeting the addition of over 1,000 franchise centres over the next two years**. In addition, we have **commenced our online business initiatives** and plan to further **scale our digital healthcare platform** in the coming years. Our preventive healthcare check-up programs continue to witness strong traction and are growing steadily across markets.

Looking ahead, we remain highly optimistic about the opportunities in the Indian diagnostics industry and continue **to focus on expanding our pan-India centre network, improving utilisation** across newly launched centres and strengthening network coverage through our partnership-led growth strategy with Jeena Sikho. As part of our long-term vision, Chandan Healthcare is also working towards **establishing a One District One Lab presence across Uttar Pradesh and Uttarakhand over the next two years**. We remain committed towards building a scalable, integrated and high-quality diagnostics platform with strong long-term growth visibility.

### Key Q4 FY26 Operational Highlights

<p><b>Accelerating Institutional Growth Through Long-Term Government Healthcare Projects</b></p>	<ul style="list-style-type: none"> <li>• Secured multiple Punjab government PPP projects across Pathankot, Gurdaspur, Tarn Taran, Batala, Hoshiarpur, SBS Nagar, Kapurthala, Dasuya, Fazilka, Mukatsar Sahib, Firozpur, Abohar involving installation of 1.5 Tesla MRI and 32-slice CT scan systems with estimated project value of ₹800 Cr in 10 years.</li> <li>• Awarded 10-year MRI project at 200-bedded Civil Hospital, Rohtak (Haryana) with installation of advanced 1.5 Tesla MRI system catering to 40,000+ monthly OPD footfall</li> <li>• Secured 10-year PPP project at Northeast Frontier Railway Central Hospital, Assam for development of advanced radiology centre equipped with 3 Tesla MRI, 128-slice CT scan, X-Ray, USG and Colour Doppler facilities</li> </ul>
<p><b>Scaling Exclusive Jeena Sikho Partnership Across High-Growth Healthcare Markets</b></p>	<ul style="list-style-type: none"> <li>• Commenced diagnostic operations at 100+ bed HIIMS partner hospital facility in Dera Bassi, marking entry into Punjab through integrated institutional healthcare model with captive IPD and OPD demand</li> <li>• Expanded operations through 600+ bed partner hospital facility in Muradnagar, Meerut and commenced operations at integrated hospital facility in Kurukshetra, strengthening presence across key North Indian markets</li> <li>• Expanded operations in Lucknow and commenced diagnostic operations in Kota, Rajasthan, further strengthening multi-city rollout under exclusive Jeena Sikho partnership network</li> </ul>

### Strengthening Network Reach Across Metro and Emerging Cities

- Entered Maharashtra through launch of Mumbai diagnostic centre offering pathology and advanced diagnostic services including TMT, ECG, EEG and PFT with planned addition of X-Ray and BMD services
- Entered West Bengal through launch of Kolkata diagnostic centre focused on comprehensive blood investigations with planned addition of X-Ray and BMD capabilities supporting integrated network expansion
- Entered Chandigarh through launch of diagnostic centre focused on comprehensive blood investigations with planned addition of X-Ray and BMD capabilities supporting integrated network expansion
- Entered Chhattisgarh through launch of Raipur diagnostic centre offering pathology and advanced diagnostic services including TMT, ECG, EEG and PFT with provision for future CT and MRI facilities

### About Chandan Healthcare Limited

Chandan HealthCare Limited, established in 2003, is a leading Pan India-based diagnostics company and a part of the Chandan Group. The company has a strong presence in 13 states including Chandigarh, Bihar, West Bengal, Chattisgarh, Madhya Pradesh, Maharashtra, Gujarat, Assam, Delhi, Punjab, Haryana, Uttar Pradesh, Uttarakhand. It offers comprehensive pathology, radiology, and diagnostic services under one roof, operating 65+ diagnostic centers and over 400 collection centers. Chandan's customer-centric, company-owned model builds trust and ensures quality. Its pharmacy division, Chandan Pharmacy Limited, complements its integrated healthcare offerings.

### Key Strengths & Achievements

- **One-Stop Diagnostics:** Delivers over 3,500 pathology and radiology tests through 12 NABL-accredited labs and 5 NABH MIS-accredited centres, supported by 1,600 skilled professionals.
- **Consistent Quality:** Ensures high standards via a company-operated model, backed by experienced leadership and a loyal workforce.
- **Diversified Revenue Streams:** Serves B2C, B2B and B2G markets, including individual diagnostics, hospital partnerships, and government contracts, alongside a growing pharmacy division.
- **Cost-Efficient Operations:** Uses refurbished and new high-end machines to optimise costs while maintaining test accuracy.
- **Customer Loyalty:** Drives repeat business through localised pricing, personalised care, and a strong presence in underserved Tier 2/3 markets.
- **Robust Financials:** In F.Y.26, total Income of ₹280.67 Cr, EBITDA of ₹56.84 Cr and PAT of ₹27.06 Cr. reflecting strong growth and operational efficiency.

### Scale & Growth Trajectory

- **Expanding Footprint:** Operates across Uttar Pradesh, Uttarakhand, Rajasthan, Bihar, Madhya Pradesh, and Delhi, with upcoming centres planned in Chhattisgarh, Western Uttar Pradesh and other states.
- **Chandan Medical Centres (CMCs):** Innovative local hubs offering collection, pharmacy, and teleconsultation services to penetrate new markets.
- **Strategic Growth:** Expanding in 13 states including Chandigarh, Bihar, West Bengal, Chhattisgarh, Madhya Pradesh, Maharashtra, Gujarat, Assam, Delhi, Punjab, Haryana, Uttar

Pradesh, Uttarakhand through selective franchising for pathology services, while enhancing digital platforms and direct-to-consumer channels to drive scalable growth.

Chandan HealthCare is a trusted leader in diagnostics, blending a strong PAN INDIA presence with disciplined expansion and customer-focused innovation. With robust financials and a clear growth strategy, it is well-positioned to deliver value to investors and transform healthcare across emerging and metro markets.

The company was listed on NSE Emerge on 17<sup>th</sup> February 2025.

#### Disclaimer

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

#### For Further Information Please Contact Corporate Communication Advisor



##### Kirin Advisors Private Limited

Sunil Mudgal - Director

[sunil@kirinadvisors.com](mailto:sunil@kirinadvisors.com)

+91 98692 75849

[www.kirinadvisors.com](http://www.kirinadvisors.com)